戻る Agenda
Real-World Evidence (RWE) in Drug Development – Creating the Right Environment for Enhanced Pre-Launch Evidence
Session Chair(s)
Pieter Stolk, PHARMD, PHD
Project Manager
University Medical Centre Utrecht, Netherlands
Real-World Evidence (RWE) in Drug Development – Creating the Right Environment for Enhanced Pre-Launch Evidence
Speaker(s)
How Can Future Pre-Launch Studies Provide Information on the Relative Effectiveness of a New Medicine: Lessons from the Influence of ‘Real-World Data’ on the Reassessment of Pharmaceuticals
François Meyer, MD
French National Authority for Health (HAS), France
Advisor to the President, International Affairs
What are the Operational/Feasiblity Challenges in Conducting RWE Studies – Pragmatic Trials, As an Example
Iris Goetz, MD, MSC
Eli Lilly and Company, United Kingdom
Epidemiologist, Global Health Outcomes
Acceptability of RWE: A Key Factor for R&D Decision-Making Pre- vs Post- Launch
Chris Chinn, MSC
Sanofi, United Kingdom
Real World Evidence for Market Access